Angle (AGL)

 

AGL Share PerformanceMore

52 week high82.50 21/03/16
52 week low46.55 04/01/17
52 week change -17.75 (-26.39%)
4 week volume2,757,079 23/12/16

Media for (AGL)

Presenter: Andrew Newland, Chief Executive
09/10/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ANGLE Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017

Andrew Newland the Chief Executive of ANGLE Plc (AGL) [LSE:AGL] the specialist medtech company, is to present at th...

ANGLE schedules interims

ANGLE, the specialist medtech company, will be releasing its interim results for the six months ended 31 October on 26 Jan...

Notice of Results

RNS Number: 2482T Angle PLC 04 January 2017 For Immediate Release 04 January 2017 ANGLE plc ("ANGLE" or "the Company") Notification of Interim Results and Webcast ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, will be releasing its interim results for the six months ended 31 October 2016 on Thursday 26 January 2017. ...

Our AIM tip soars 60% in 2016

Matching our huge success in 2015 would always be difficult, but former AIM writer of the year Andrew Hore still mana...

ISSUE OF SHARE OPTIONS

RNS Number: 2366Q Angle PLC 28 November 2016 For immediate release 28 November 2016 ANGLE plc ("ANGLE" or the "Company") ISSUE OF SHARE OPTIONS ANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that under the shareholder approved Remuneration Policy the Remuneration Committee has approved the issu...

Result of GM

RNS Number: 1072Q Angle PLC 24 November 2016 For Immediate Release 24 November 2016 ANGLE plc ("ANGLE" or "the Company") Result of 24 November 2016 General Meeting ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, announces that the Resolution put to its shareholders at today's General Meeting was duly passed. For furt...

ANGLE welcomes new research supporting Parsortix

ANGLE, the specialist medtech company, welcomes new research which supports the potential use of the company's Parso...

Barts Research Supports Potential Use of Parsortix

RNS Number: 2829O Angle PLC 04 November 2016 For immediate release 4 November 2016 ANGLE plc ("ANGLE" or "the Company") ANGLE WELCOMES NEW RESEARCH FROM BARTS SUPPORTING POTENTIAL USE OF PARSORTIX TO DETECT AND MONITOR PROSTATE CANCER Simple blood test could become effective diagnostic ANGLE p...

Fundamental DataMore

EPS-8.64
Dividend yield0 %

Equity Research (AGL)

ANGLE Plc
15/11/2016
Angle (AGL.L) 58.5p £43.77m The specialist medtech company, has welcomed new research presented during the National Cancer Research Institute annual conference, 6-9 November 2016, which supports the...
edison investment research
ANGLE Plc
02/08/2016
Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercializing the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing...
edison investment research
ANGLE Plc
01/08/2016
Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercialising the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing...

Latest discussion posts More

  • Re: Hopefully bottemed out now

    Presenting in the US next week - they must have something decent to say or it wouldn't be worth the bother.
    7-Jan-2017
    autpaxautbellum
  • Hopefully bottemed out now

    I've averaged down a bit...fingers crossed for some good results in 3 weeks. Anyone got any info on how things are going ?
    6-Jan-2017
    Good money after bad
  • Re: Forget it ....... !

    Thanks for that. I have just accidentally picked up the iii tips for 2016, less successful than the ones for 2015! If you work your way through to the final one, it was ...
    29-Dec-2016
    claude reins

Users' HoldingsMore

Users who hold Angle also hold..
LLOYDS GRP.22%
TESCO21%
GLAXOSMITHKLINE14%
VODAFONE GRP.13%
SIRIUS MINERALS12%

Codes & Symbols

ISINGB0034330679
SymbolsAGL, LSE:AGL, AGL.L, AGL:LN, LON:AGL, XLON:AGL